Skip to main content
SpringerLink
Log in

Effectiveness of thrombolysis in patients with intermediate-risk pulmonary embolism: Influence on length of hospital stay

  • Original Research
  • Published:
Advances in Therapy Aims and scope Submit manuscript

Abstract

Introduction

The effects of thrombolysis on the clinical outcome of patients with intermediate-risk pulmonary embolism (PE) are still under debate. The effect of thrombolysis on the length of stay (LOS) in hospital is unknown. The aim of this study was to identify factors associated with LOS and to investigate whether LOS is suitable to assess effectiveness of thrombolysis in patients with intermediate-risk PE.

Methods

Data were reviewed from December 2005 until October 2009. The LOS in the intensive care unit (ICU) was expressed in hours, and total LOS was recorded in days. Total LOS was not noted in case of preterm withdrawal of therapy or death.

Results

Of a total of 202 patients, 84 received alteplase plus heparin and 118 patients were treated with anticoagulants alone. Total median LOS was significantly shorter (10 vs. 12 days) in the alteplase group (P=0.005), while there was no difference in the LOS in the ICU. Age above 65 years (P=0.036) and comorbidity (P<0.001) were independent predictors for a prolonged hospital stay, whereas thrombolysis independently predicted a shorter total LOS in multivariate analysis (P=0.001). Thrombolysis has shown to be able to independently predict home discharge (P=0.029).

Conclusion

LOS is influenced by patient-related factors such as age and comorbidity. Thrombolysis may lead to a reduction of total median LOS for patients with intermediate-risk PE, possibly indicating that it is more effective than anticoagulant therapy alone in this group of patients.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Dalen JE, Alpert JS, Hirsch J. Thrombolytic therapy for pulmonary embolism: is it effective? Is it safe? When is it indicated? Arch Intern Med. 1997;157:2550–2556.

    Article  CAS  PubMed  Google Scholar 

  2. Torbicki A, Perrier A, Konstantinides S, et al. Task Force for the Diagnosis and Management of Acute Pulmonary Embolism of the European Society of Cardiology. Guidelines on the diagnosis and management of acute pulmonary embolism: the Task Force for the Diagnosis and Management of Acute Pulmonary Embolism of the European Society of Cardiology (ESC). Eur Heart J. 2008;29:2276–2315.

    Article  CAS  PubMed  Google Scholar 

  3. Todd JL, Tapson VF. Thrombolytic therapy for acute pulmonary embolism: a critical appraisal. Chest. 2009;135:1321–1329.

    Article  CAS  PubMed  Google Scholar 

  4. Konstantinides S, Geibel A, Heusel G, Heinrich F, Kasper W. Heparin plus alteplase compared with heparin alone in patients with submassive pulmonary embolism. N Engl J Med. 2002;347:1143–1150.

    Article  CAS  PubMed  Google Scholar 

  5. Goldhaber SZ, Visani L, De Rosa M. Acute pulmonary embolism: clinical outcomes in the International Cooperative Pulmonary Embolism Registry (ICOPER). Lancet. 1999;353:1386–1389.

    Article  CAS  PubMed  Google Scholar 

  6. Perlroth DJ, Sanders GD, Gould MK. Effectiveness and cost-effectiveness of thrombolysis in submassive pulmonary embolism. Arch Intern Med. 2007;167:74–80.

    Article  PubMed  Google Scholar 

  7. Ramakrishnan N. Thrombolysis is not warranted in submassive pulmonary embolism: a systematic review and meta-analysis. Crit Care Resusc. 2007;9:357–363.

    PubMed  Google Scholar 

  8. Zamanian RT, Gould MK. Effectiveness and cost effectiveness of thrombolysis in patients with acute pulmonary embolism. Curr Opin Pulm Med. 2008;14:422–426.

    Article  PubMed  Google Scholar 

  9. Kucher N, Rossi E, De Rosa M, Goldhaber SZ. Prognostic role of echocardiography among patients with acute pulmonary embolism and a systolic arterial pressure of 90 mm Hg or higher. Arch Intern Med. 2005;165:1777–1781.

    Article  PubMed  Google Scholar 

  10. Hunt PJ, Richards AM, Nicholls MG, Yandle TG, Dougthy RN, Espiner EA. Immunoreactive aminoterminal pro-brain natriuretic peptide (NTproBNP): a new marker for cardiac impairment. Clin Endocrinol. 1997;47:287–296.

    Article  CAS  Google Scholar 

  11. Gorissen C, Baumgarten R, de Groot M, van Haren E, Kragten H, Leers M. Analytical and clinical performance of three natriuretic peptide tests in the emergency room. Clin Chem Lab Med. 2007;45:678–684.

    Article  CAS  PubMed  Google Scholar 

  12. Hildebrandt P, Collinson PO. Amino-terminal pro-B-type natriuretic peptide testing to assist the diagnostic evaluation of heart failure in symptomatic primary care patients. Am J Cardiol. 2008;10(suppl. 3A):25–28.

    Article  Google Scholar 

  13. Hafner G, Peetz D, Dati F, et al. Analytical and clinical evaluation of troponin I determination on dimension RXL-HM. Clin Chem Lab Med. 2000;38:355–361.

    Article  CAS  PubMed  Google Scholar 

  14. Aujesky D, Stone RA, Kim S, Crick EJ, Fine MJ. Length of hospital stay and postdischarge mortality in patients with pulmonary embolism: a statewide perspective. Arch Intern Med. 2008;168:706–712.

    Article  PubMed  Google Scholar 

  15. Goldhaber SZ, Come PC, Lee RT, et al. Alteplase versus heparin in acute pulmonary embolism: randomised trial assessing right-ventricular function and pulmonary perfusion. Lancet. 1993;341:507–511.

    Article  CAS  PubMed  Google Scholar 

  16. Dalla-Volta S, Palla A, Santolicandro A, et al. PAIMS 2: alteplase combined with heparin versus heparin in the treatment of acute pulmonary embolism. Plasminogen activator Italian multicenter study 2. J Am Coll Cardiol. 1992;20:520–526.

    Article  CAS  PubMed  Google Scholar 

  17. Konstantinides S, Tiede N, Geibel A, Olschewski M, Just H, Kasper W. Comparison of alteplase versus heparin for resolution of major pulmonary embolism. Am J Cardiol. 1998;82:966–970.

    Article  CAS  PubMed  Google Scholar 

  18. Goldhaber SZ. Thrombolysis for pulmonary embolism. N Engl J Med. 2002;347:1131–1132.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Academic Teaching Hospital of the Ludwig-Maximilians-University Munich, Stenglinstrasse 2, D-86156, Augsburg, Germany

    T. M. Berghaus, C. Thilo, A. Bluethgen, W. von Scheidt & M. Schwaiblmair

Authors
  1. T. M. Berghaus
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. C. Thilo
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. A. Bluethgen
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. W. von Scheidt
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. M. Schwaiblmair
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to T. M. Berghaus.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Berghaus, T.M., Thilo, C., Bluethgen, A. et al. Effectiveness of thrombolysis in patients with intermediate-risk pulmonary embolism: Influence on length of hospital stay. Adv Therapy 27, 648–654 (2010). https://doi.org/10.1007/s12325-010-0058-x

Download citation

  • Received:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12325-010-0058-x

Keywords

Search

Navigation